/ /

  • linkedin
  • Increase Font
  • Sharebar

    In the pipeline: What’s new and what’s coming in optometry technology

     

    Punctal plug delivery

    The Dextenza punctal plug by Ocular Therapeutix is placed into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days. Following treatment, Dextenza resorbs and exits the nasolacrimal system without the need for removal.

    Imprimis Dropless Therapy

    Impris Dropless Therapy uses a compounded antibiotic and steroid formulation in single, injectable doses administered by physicians following ocular surgery. The treatment is designed to eliminate the need for patient-administered eye drops, potentially eliminating patient non-compliance or dosing errors. Imprimis Dropless Therapy offers additional potential in the marketplace.

    Bausch + Lomb Vyzulta

    This nitrious oxide sparing prostaglandin analogue is likely to be approved by the FDA in late summer 2017. It is the first drop to show improvement over timolol in lowering IOP in its FDA trial. Vyzulta lowered IOP by 9.1 mm compared to 7.3 mm for timolol in Phase III trials.

    Rhopressa and Roclatan

    Aerie Pharmaceuticals Rhopressa (netarsudil ophthalmic solution) and Roclatan (a combination drug containing both Rhopressa and generic latanoprost) promise new methods of action in the treatment of glaucoma.

    Related: Tools ODs can utilize to diagnose, treat glaucoma

    Anti-viral

    Shire’s anti-viral involves povidone iodine and dexamethasone. Povidine iodine currently is used as an antiseptic peri-operatively as well as for epidemic keratoconjunctivitis. Often times significant inflammation is associated with povidine, so dexamethasone is included.

    Zerviate

    FDA-approved Zerviate is the first approved new drug application for Nicox. It is the first topical ocular formulation of the antihistamine cetirizine. Nicox will partner with another company for U.S. commercialization rights.

    Luminesse

    Luminesse by Bausch + Lomb is a topical vasoconstrictor formulation to be used over-the-counter to relieve ocular redness due to minor eye irritations. It is a low-dose alpha adrenergic that whitens eyes 300 percent better than Visine. The effects last four to eight hours.

    Lampalizumab

    Developed by Roche, lampalizumab is the first potential treatment for geographic atrophy. Currently, no approved treatment exists for this advanced form of age-related macular degeneration (AMD). Two identical phase III studies are evaluating potential benefit of lampalizumab on geographic atrophy lesions.

    Novartis RTH258

    Novartis’ RTH258 is an injection for wet AMD. It is a single-chain antibody fragment VEGF inhibitor. RTH258 has shown long-lasting efficacy dosed every eight weeks compared with aflibercept. 

    Read more from Optometry's Meeting in Washington, DC here

    Giovanni Castelli
    Giovanni Castelli is the content specialist for Optometry Times. He is a 2014 graduate of Cleveland State University with a degree in ...

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Optometry Times A/V